Cystic fibrosis (CF) is a potentially fatal genetic disease characterized by the build-up of thick, sticky mucus and infection that can damage many of the body’s organs.
CF causes repeat and persistent lung infections that result in frequent exacerbations, sudden severe flare-ups of symptoms, and hospitalizations. Patients endure multiple daily medications, frequent hospitalizations and, ultimately, selected patients have lung transplants.
The quality of life for CF patients is compromised as a result of spending significant time on self-care every day and frequent medical visits and hospitalizations. The US and European regulatory authorities consider CF to be a rare, or orphan, disease and provide incentives to encourage development of effective new treatments.
According to the Cystic Fibrosis Foundation, approximately 40,000 people in the US and an estimated 105,000 people worldwide have been diagnosed with CF across 94 countries.
Chronic obstructive pulmonary disease (COPD) is a progressive lung condition without a cure. It damages the airways and lungs, leading to debilitating breathlessness.
Non-Cystic Fibrosis Bronchiectasis (NCFB) is a chronic lung disease with no FDA-approved treatment. Patients suffer from persistent cough, excess sputum production and frequent respiratory infections.
Asthma is a common chronic inflammatory disease that makes it harder to move air in and out of the lungs.
We welcome inquires from healthcare professionals seeking to learn more.